Oric Pharmaceuticals Inc.
NASDAQ · ORIC·South San Francisco, CA·Small-cap·Phase 2
Clinical-stage biotech developing small molecule therapies to overcome treatment resistance in cancer. Lead programs target prostate cancer (rinzimetostat, a PRC2/EED inhibitor) and NSCLC (enozertinib, a brain-penetrant EGFR inhibitor), both advancing toward Phase 3 registrational trials.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| ORIC Pharmaceuticals Company Presentation March 2026 | Corporate overview | March 1, 2026 | 50 |